2007
DOI: 10.1007/s11259-007-0103-7
|View full text |Cite
|
Sign up to set email alerts
|

The Use of Alpha-2 Agonists in the Equine Practice: Comparison between Three Molecules

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

1
18
1
1

Year Published

2012
2012
2022
2022

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 14 publications
(21 citation statements)
references
References 3 publications
1
18
1
1
Order By: Relevance
“…1a) and therefore might also be attributed to transiently deeper sedation with xylazine. Contrary to our results, previous studies showed that instability and ataxia were significantly less with romifidine compared to other alpha 2adrenergic agonists (England et al 1992;Hamm et al 1995;Nannarone et al 2007). However, it might be possible that during CRI, horses learn to counterbalance the instability making differences between treatments less evident over time in the present study.…”
Section: Discussioncontrasting
confidence: 99%
“…1a) and therefore might also be attributed to transiently deeper sedation with xylazine. Contrary to our results, previous studies showed that instability and ataxia were significantly less with romifidine compared to other alpha 2adrenergic agonists (England et al 1992;Hamm et al 1995;Nannarone et al 2007). However, it might be possible that during CRI, horses learn to counterbalance the instability making differences between treatments less evident over time in the present study.…”
Section: Discussioncontrasting
confidence: 99%
“…Ketamine, combined with guaifenesin, 16 lidocaine, 17 medetomidine, and guaifenesin 18 or medetomidine and benzodiazepines, 19 has been the drug most commonly used for this purpose. 24,25 For this reason, it could represent a useful adjunct to ketamine for PIVA in horses. 22,23 Among α 2 -adrenergic receptor agonists, romifidine provides longer lasting analgesia and less ataxia, compared with equipotent sedative doses of xylazine, detomidine, and romifidine.…”
mentioning
confidence: 99%
“…En este estudio se puede afirmar que la actividad motora espontánea tanto al paso como al trote, no se ve alterada con acepromacina a 0.04 mg/kg. Las alteraciones en el patrón locomotor son debidas a una depresión del SNC, a diferencia del efecto sedante y miorrelajante descrito para los fármacos agonistas de los receptores α2 (Nannarone et al, 2007).…”
Section: Discussionunclassified